Ardea earns $15 million milestone from Bayer as anticancer moves into Phase II
This article was originally published in Scrip
Executive Summary
Ardea Biosciences, based in San Diego California, earned a $15 million milestone payment from Bayer under the terms of their April 2009 global licence agreement to develop and commercialise the US firm's mitogen-activated ERK kinase (MEK) inhibitor compounds for cancer and other indications.